PYXS NASDAQ
Credit Risk of going bust: higher than 81% of companies Debt: 14.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.2%), Pyxis Oncology, Inc. would be worth roughly what it owes.
Total debt $17.8M against a stock market value of $107.1M.
Distance to default 2.50 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.8M (short-term plus half of long-term), stock volatility 132.9%; Altman Z'' -38.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Boston, MA 02118
US
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| GordonMD Global Inve | P-Purchase | 7,172,000 | $3.50 | 2026-10-01 |
| GordonMD Global Inve | P-Purchase | 5,517,000 | — | 2026-10-01 |
| GordonMD Global Inve | P-Purchase | 7,546,766 | $3.50 | 2026-10-01 |
| Civik Thomas | A-Award | 2,503,050 | $3.89 | 2026-09-04 |
| Dupont Jakob | A-Award | 46,000 | $3.12 | 2026-08-20 |